{
    "clinical_study": {
        "@rank": "47095", 
        "arm_group": [
            {
                "arm_group_label": "VITICELL", 
                "arm_group_type": "Experimental", 
                "description": "In this arm, lesions will be treated by autologous epidermal cells suspension (containing hyaluronic acid) obtained after VITICELL kit's use, a class III medical device."
            }, 
            {
                "arm_group_label": "PLACEBO", 
                "arm_group_type": "Sham Comparator", 
                "description": "In this arm, lesions will be treated by a suspension of hyaluronic acid without epidermal cells."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy of autologous epidermal cells suspension\n      grafting using a newly developed device named VITICELL\u00ae compared to placebo.\n\n      The secondary objective is to evaluate safety of VITICELL\u00ae and global satisfaction of\n      patient and investigator."
        }, 
        "brief_title": "A Multicenter Trial of Non-cultured Epidermal Cellular Grafting Versus Hyaluronic Acid for Repigmenting Stable Leukoderma (Vitiligo and Piebaldism)", 
        "condition": [
            "Vitiligo", 
            "Piebaldism"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Vitiligo", 
                "Piebaldism"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women aged over 18 years old with a diagnosis of non-scaring leukoderma that\n             has been stable over the last 2 years (non-segmental, segmental vitiligo and\n             piebaldism)\n\n          -  For non-segmental vitiligo: symmetrical vitiligo lesions, or parts of a lesion. A\n             part of at least 1 cm2 (1 x 1 cm), but preferable 4 cm2 (2x2 cm) and preferably in\n             the center of each lesions (left/right) should be treated.\n\n        The minimum distance between the normal pigmented skin and the test area should preferably\n        be at least 0.5 cm.\n\n          -  For segmental vitiligo lesion and piebaldism: all lesions possible if two parts of at\n             least 1 cm2 (1 x 1 cm), but preferably 4 cm2 (2 x 2 cm) in the lesion can be treated.\n             The minimum distance between the 2 areas should be 2 cm and between test areas and to\n             the normal pigmented skin preferably at least 0.5 cm.\n\n          -  Medical treatments of vitiligo failed (in case of vitiligo: at least cream treatment\n             for 6 months).\n\n          -  Absence of infected lesion\n\n          -  Negative serology (HIV-hepatitis B and C- Syphilis)\n\n          -  Without treatment one month for cream and 3 months for phototherapy\n\n        Exclusion Criteria:\n\n          -  Hypersensibility to local anaesthetics or one of the components of the device\n             (trypsin, hyaluronic acid)\n\n          -  Indication against biopsies\n\n          -  Patient with a history of melanoma\n\n          -  Positive serology (ongoing serious systemic disease, herpes, HIV, hepatitis B and\n             C-Syphilis)\n\n          -  Positive pregnancy test\n\n          -  History of keloidal scars and presence of Koebner's phenomenon (type 1 and type 2b)\n\n          -  Infected lesion\n\n          -  Test areas not on fingers and toes vitiligo areas in case of non-segmental vitiligo\n\n          -  Test areas not on facial non segmental vitiligo\n\n          -  Pregnant women, or lactating\n\n          -  Age <18years\n\n          -  Major deprived of their freedom by administrative or legal decision, or being the\n             subject of a legal protection measure, or out of state to express their consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02156427", 
            "org_study_id": "13INT/VIT01"
        }, 
        "intervention": [
            {
                "arm_group_label": "VITICELL", 
                "intervention_name": "VITICELL", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "PLACEBO", 
                "intervention_name": "PLACEBO", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hyaluronic Acid"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Nanja.vangeel@UGent.be", 
                    "last_name": "Nanja van Geel, Prof. Dr.", 
                    "phone": "+ 32-93322298"
                }, 
                "facility": {
                    "address": {
                        "city": "Ghent", 
                        "country": "Belgium"
                    }, 
                    "name": "Department of Dermatology - Ghent University Hospital"
                }, 
                "investigator": {
                    "last_name": "Nanja Van Geel, Prof. Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France"
                    }, 
                    "name": "University Hospital Center of Bordeaux"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "San Gallicano Dermatological Institute"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "France", 
                "Italy"
            ]
        }, 
        "number_of_arms": "2", 
        "other_outcome": {
            "measure": "Number of adverse events in each group", 
            "safety_issue": "Yes", 
            "time_frame": "Day 0/Day 6-7/Month 3/6/9/12"
        }, 
        "overall_contact": {
            "email": "khaled.ezzedine@chu-bordeaux.fr", 
            "last_name": "Khaled Ezzedine, Dr.", 
            "phone": "+ 33 (0)5 56 79 49 62"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: National Agency for Medicines and Health Products Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Successful repigmentation: more than or equal to 50% repigmentation of the treated area", 
            "safety_issue": "No", 
            "time_frame": "up to month 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02156427"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Repigmentation rate \u2265 50% of the treated area", 
            "safety_issue": "No", 
            "time_frame": "month 12"
        }, 
        "source": "Laboratoires Gen\u00e9vrier", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Laboratoires Gen\u00e9vrier", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}